- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT01960530
Un estudio de investigación de hidrocortisona
Un estudio abierto, parcialmente aleatorizado, de dosis única, cruzado para evaluar la farmacocinética, la biodisponibilidad oral y la relación con los parámetros metabólicos de hidrocortisona e Infacort® en voluntarios varones adultos sanos.
This study will investigate a new drug called Infacort®; a newly-developed immediate release formulation of a well-established drug called hydrocortisone. Hydrocortisone is used as a replacement treatment for people whose adrenal glands are not producing enough natural cortisol - a condition known as adrenal insufficiency. The study will assess how Infacort® acts once inside the body, by measuring cortisol and other hormone levels in the body, compared to already marketed hydrocortisone tablet and hydrocortisone intravenous (through the vein) injection.
The population who are eligible to take part in the study are healthy male volunteers, aged between 18 and 60 years of age.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
The study will evaluate the normal physiology, PK and metabolism of cortisol, investigate the PK and bioavailability of cortisol from the test Infacort® Granules (hydrocortisone) and the reference hydrocortisone tablets and i.v injection in healthy adult male volunteers and explore the role of cortisol in the regulation of metabolic pathways.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Merthyr Tydfil, Reino Unido, CF48 4DR
- Simbec Research Limited
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Healthy male volunteers between 18 and 60 years of age, inclusive (at screening).
-
Subjects with a Body Mass Index (BMI) of 21-28. Body Mass Index = Body weight (kg) / (Height (m))*2.
-
Subjects with no clinically significant abnormal serum biochemistry, haematology and urinalysis values within 14 days prior to Day 1 of Study Period 1.
-
Subjects with a negative urinary drugs of abuse screen, determined within 14 days prior to Day 1 of Study Period 1. A positive alcohol test may be repeated at the discretion of the Investigator.
-
Subjects with negative HIV and Hepatitis B and C results.
-
Subjects with no clinically significant abnormalities in 12-lead electrocardiogram (ECG) determined within 14 days prior to Day 1 of Study Period 1.
-
Subjects with no clinically-significant deviation outside the normal ranges for blood pressure and pulse measurements.
-
Subjects (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) and sexual partners must use effective contraception methods during the trial and for 3 months after the last dose, for example:
- Oral contraceptive + condom
- Intra-uterine device (IUD) + condom
- Diaphragm with spermicide + condom
-
Subjects must be available to complete the study.
-
Subjects must satisfy a medical examiner about their fitness to participate in the study.
-
Subjects must provide written informed consent to participate in the study.
Exclusion Criteria:
- A clinically significant history of gastrointestinal disorder likely to influence drug absorption.
- Receipt of regular medication within 14 days prior to Day 1 of Study Period 1 (including high dose vitamins, dietary supplements or herbal remedies).
- Receipt of any vaccination within 14 days prior to Day 1 of Study Period 1.
- Evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction.
- Presence of clinically significant infections (systemic fungal and viral infections, acute bacterial infections).
- Current or previous history of tuberculosis.
- A clinically significant history of previous allergy / sensitivity to Hydrocortisone and/or Dexamethasone.
- A clinically significant history or family history of psychiatric disorders/illnesses.
- A clinically significant history of drug or alcohol abuse.
- Inability to communicate well with the Investigator (i.e., language problem, poor mental development or impaired cerebral function).
- Participation in a New Chemical Entity clinical study within the previous 4 months or a marketed drug clinical study within the previous 3 months. (N.B. The washout period between trials is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study)
- Subjects who have consumed more than 2 units of alcohol per day within seven (7) days prior to Day 1 of Study Period 1or have consumed any alcohol within the 48 hour period prior to Day 1 of Study Period 1.
- Donation of 450ml or more of blood within the previous 3 months.
- Subjects who smoke (or ex-smokers who have smoked within 6 months prior to Day 1 of Study Period 1).
- Subjects who work shifts (i.e. regularly alternate between days, afternoons and nights).
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Endogenous Cortisol
No Study medication will be given during this study period, however various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
|
|
Otro: Dexamethasone
1mg Dexamethasone will be administered at 22:00 on Day 1 and at 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. Dexamethasone is considered a challenge agent and therefore a non-IMP |
Challenge agent
Otros nombres:
|
|
Experimental: Infacort®
20mg Infacort® will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous adrenocorticotropic Hormone (ACTH) and cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Multi-particulate granules
Otros nombres:
|
|
Comparador activo: Hydrocortisone Tablet
20mg Hydrocortisone Tablet will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Standard hydrocortisone tablets
Otros nombres:
|
|
Comparador activo: i.v Hydrocortisone Injection
20mg i.v. Hydrocortisone Injection will be administered on Day 2 at 07:00. Dexamethasone is a challenge agent and will be taken to suppress endogenous ACTH and Cortisol. 1mg Dexamethasone will be administered at 22:00 on Day 1 and 06:00 and 12:00 on Day 2. Various blood, urine and saliva samples will be taken in order to measure normal levels of hormones and other chemicals at several time-points. |
Standard hydrocortisone solution for intravenous injection
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum Serum Concentration (Cmax)
Periodo de tiempo: Hourly from 0 to 24 hours
|
Derived PK for Serum Cortisol: Maximum serum concentration (Cmax) |
Hourly from 0 to 24 hours
|
|
AUC0-t
Periodo de tiempo: Hourly from 0 to 24 hours
|
Derived PK for Serum Cortisol: Area under the curve from 0-24 hours |
Hourly from 0 to 24 hours
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse Events (AEs)
Periodo de tiempo: Days 1-2 during each Study Period
|
Number of subjects with adverse events throughout the study. |
Days 1-2 during each Study Period
|
|
Concentrations of Cortisol Binding Protein
Periodo de tiempo: Blood samples on Day 1 and/or Day 2 of each Study Period
|
Cortisol protein binding under physiological conditions and after the administration of dexamethasone and hydrocortisone. |
Blood samples on Day 1 and/or Day 2 of each Study Period
|
|
Insulin Sensitivity Under Physiological Conditions and After Administration of Dexamethasone and Infacort®, Hydrocortisone Tablets and i.v Hydrocortisone.
Periodo de tiempo: Blood samples on Day 1 and/or Day 2 of each Study Period
|
A standardised mixed meal elevates blood glucose and provides a reproducible stimulation of insulin release. Lower levels of insulin secretion, whilst maintaining normoglycaemia would indicate enhanced insulin sensitivity and glucose disposal; higher insulin levels will reflect insulin resistance. |
Blood samples on Day 1 and/or Day 2 of each Study Period
|
|
PK and Metabolism of Cortisol
Periodo de tiempo: Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period
|
Blood: Serum cortisol under physiological conditions and after administration of dexamethasone and Infacort® Granules, Hydrocortisone Tablets and i.v Hydrocortisone Injection. |
Blood, urine & saliva samples on Day 1 and/or Day 2 of each Study Period
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Girish Sharma, Simbec Research
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimado)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades del sistema endocrino
- Enfermedades de las glándulas suprarrenales
- Insuficiencia suprarrenal
- Hormonas
- Hormonas, sustitutos hormonales y antagonistas hormonales
- Compuestos policíclicos
- Espierra
- Embarazos
- Esteroides
- Compuestos de anillo fusionado
- Esteroides, fluorado
- Esparrazadienetrioles
- Embarazadas
- Embarazo
- 11-hidroxicorticosteroides
- Hidroxicorticosteroides
- Hormonas de la corteza suprarrenal
- 17-hidroxicorticosteroides
- Dexametasona
- Hidrocortisona
Otros números de identificación del estudio
- Infacort 002
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .